1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Research on Short-Lived and Long-Lived Plasma Cells in Humans is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). This topic encourages applications to understand the biology of Short-Lived Plasma Cells (SLPC) and Long-Lived Plasma Cells (LLPC) through characterization of plasma cell phenotypes and function in human health and disease.
Get alerted about grants like this
Get emailed when new opportunities from “National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Research on Short-Lived and Long-Lived Plasma Cells in Humans | Grants & Funding U.S. Department of Health and Human Services National Institutes of Health Research on Short-Lived and Long-Lived Plasma Cells in Humans When beginning your next investigator-initiated application, consider the following NIH highlighted topic. The area of science described below is of interest to the listed NIH Institutes, Centers, and Offices (ICOs).
This is not a notice of funding opportunity (NOFO). Apply through an appropriate NIH Parent Funding Announcement or another broad NIH opportunity available on Grants. gov .
Learn how to interpret and use Highlighted Topics . Post Date: September 10, 2025 Expiration Date: September 10, 2027 This topic encourages applications to understand the biology of Short-Lived Plasma Cells (SLPC) and Long-Lived Plasma Cells (LLPC) through characterization of plasma cell phenotypes and function in human health and disease.
The continuous production of antibodies by LLPC is critical for life-long protective humoral immunity because it does not require restimulation with antigen, unlike the requirements to activate memory B cells.
However, LLPC also produce antibodies that: Mediate some autoimmune diseases Promote allergic responses Mediate organ/tissue transplant rejection Limit patient access to organ transplantation via pre-sensitization LLPC cannot be easily depleted by most drugs currently used to deplete B cells.
In contrast, SLPC have reduced survival programming, generally produce lower affinity antibodies, and are susceptible to B cell depletion therapies. LLPC may arise from a subset of SLPC or from distinct differentiation pathways compared to SLPC; although details of the pathways, mediators, and mechanisms of SLPC and LLPC generation remain to be elucidated.
This topic encourages applications that include: Ex vivo analysis of human samples New approach methodologies (NAMs) Computational modeling of plasma cells in human health and disease Central Scientific Contact: National Institute of Allergy and Infectious Diseases (NIAID) This topic will provide foundational information for rational vaccine design to promote Long-Lived Plasma Cells (LLPC) for durable immunity; diminish LLPC or their activity in autoimmune and allergic diseases, and organ transplantation; or redirect plasma cell fate differentiation to the Short-Lived Plasma Cell (SLPC) population.
Examples of research areas associated with protective or pathogenic immune responses in infectious, immune-mediated or allergic diseases include: Identification/characterization of precursor subsets of SLPC or LLPC. Characterization of tissue sites and local factors that promote bone marrow engraftment, differentiation, and persistence or residence at alternative sites, e.g., mucosa.
Effects of host factors (age, microbiome, etc) on SLPC and LLPC differentiation and function. Comparison of antigen types and formats (soluble, membrane bound) promoting LLPC vs SLPC. National Institute on Aging (NIA) Examples of research areas relevant to the National Institute on Aging (NIA): Changes in the biology of plasma cell subpopulations during aging.
Functional impact of aging phenotypes such as cardiac amyloidosis, frailty, and cognitive decline in plasma cell disorders. Geroscience interventions to enhance effective immune response, delay or potentially reverse immune aging in patients with plasma cell disorders. Mulualem E.
Tilahun, D. V. M.
, Ph. D.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Office of Research on Women's Health (ORWH) The Office of Autoimmune Disease Research in the Office of Research on Women’s Health (OADR-ORWH) is interested in research focusing on: Understanding the relationship between Short-Lived Plasma Cells (SLPC)and Long-Lived Plasma Cells (LLPC) and how LLPC mediates autoantibody production in pre-clinical autoimmunity and autoimmune disease Study the sex influences in vaccine research utilizing the new approach methodologies (NAMs) and computational modeling of plasma cells in human health and disease.
Accelerating scientific discovery in diagnosis, treatment, prevention, and cures and enhancing health for people with autoimmune disease. This office does not award grants. Applications must be relevant to the objectives of at least one of the participating NIH Institutes and Centers listed in this topic.
Victoria Shanmugam, MBBS, MRCP, FACR, CCD For technical issues E-mail OER Webmaster
According to the current listing, eligibility includes: Investigator-initiated applications from various institutions, including academic and research institutions. Confirm the full requirements in the official notice before applying.
Applications for Research on Short-Lived and Long-Lived Plasma Cells in Humans are due September 10, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Research on Short-Lived and Long-Lived Plasma Cells in Humans is funded by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
NOT-OD-26-112 released a draft NIH Biosafety Policy for Research Involving Biohazards on August 19, 2026. It would replace the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, extend IBC jurisdiction from engineered molecules to wild-type agents, toxins and prions, impose 24-hour incident reporting, and make the Biosafety Officer a federally defined role. Here is what actually changes and how to respond before the October 19, 2026 deadline.
Read articleNIH released a draft policy on August 27, 2026 that would require every NIH-supported clinical study to offer participants a plain-language summary of results — clinical trials within one year of completion, all other clinical research by the end of the funding period. It covers observational and behavioral research that ClinicalTrials.gov never touched. Here is the scope, the four requirements nobody has budgeted for, and what to say before the October 26 deadline.
Read articleUSDA and HHS announced Harvest to Hallways on August 24, 2026: $50M in new cafeteria infrastructure funding on top of $20M in Equipment Assistance Grants, up to $25M more in Patrick Leahy Farm to School awards for FY2026, and $30M in HHS nutrition research. Each pot has a different applicant, a different route, and a different timeline. Here is how to position for all three before the notices post.
Read article